Quick Answer
LIGAND PHARMACEUTICALS INC reported Cash And Cash Equivalents At Carrying Value of $174.93 million for the year ending 2025.
- LIGAND PHARMACEUTICALS INC showed an increase of +141.9% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from LIGAND PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2010: $3.35 million | Q1 2011: $6.03 million | Q2 2011: $3.44 million | Q3 2011: $2.25 million | Q1 2012: $9.78 million | Q2 2012: $8.89 million | Q3 2012: $7.05 million | Q1 2013: $5.04 million | Q2 2013: $5.92 million | Q3 2013: $3.27 million | Q1 2014: $12.98 million | Q2 2014: $14.54 million | Q3 2014: $180.66 million | Q1 2015: $165.77 million | Q2 2015: $108.24 million | Q3 2015: $93.77 million | Q1 2016: $31.29 million | Q2 2016: $61.35 million | Q3 2016: $86.58 million | Q4 2016: $18.75 million | Q1 2017: $10.64 million | Q2 2017: $60.22 million | Q3 2017: $32.74 million | Q1 2018: $51.02 million | Q2 2018: $151.46 million | Q3 2018: $115.56 million | Q1 2019: $105.11 million | Q2 2019: $273.05 million | Q3 2019: $225.30 million | Q1 2020: $117.53 million | Q2 2020: $115.16 million | Q3 2020: $456.92 million | Q1 2021: $31.85 million | Q2 2021: $21.86 million | Q3 2021: $23.43 million | Q1 2022: $14.99 million | Q2 2022: $5.28 million | Q3 2022: $4.12 million | Q1 2023: $88.73 million | Q2 2023: $28.45 million | Q3 2023: $19.28 million | Q1 2024: $50.09 million | Q2 2024: $18.14 million | Q3 2024: $63.62 million | Q1 2025: $47.99 million | Q2 2025: $67.67 million | Q3 2025: $139.38 million.
- Over the full 18 years of available data (2008 to 2025), LIGAND PHARMACEUTICALS INC's Cash And Cash Equivalents At Carrying Value has grown by 508.4%.
- Historical annual values: Fiscal year 2025: $174.93 million | Fiscal year 2024: $72.31 million | Fiscal year 2023: $22.95 million | Fiscal year 2022: $45.01 million | Fiscal year 2021: $19.52 million | Fiscal year 2020: $47.62 million | Fiscal year 2019: $71.54 million | Fiscal year 2018: $117.16 million | Fiscal year 2017: $20.62 million | Fiscal year 2016: $18.75 million | Fiscal year 2015: $97.43 million | Fiscal year 2014: $160.20 million | Fiscal year 2013: $11.64 million | Fiscal year 2012: $12.38 million | Fiscal year 2011: $7.04 million | Fiscal year 2010: $3.35 million | Fiscal year 2009: $16.03 million | Fiscal year 2008: $28.75 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: